Overview

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Status:
Completed

Trial end date:
2018-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to determine how effective and safe the study drug Olokizumab is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully responding to, treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.

Phase:

Phase 3

Details

Lead Sponsor:

R-Pharm
R-Pharm International, LLC

Collaborators:

Mene Research
OCT Clinical Trials
Quintiles, Inc.

Treatments:

Methotrexate